Content Hub

White Papers

Articles

Presentations

Webinars

NEWLY ADDED!

Bringing It All Together – From Early Technology Evaluations to Commercial Approval

There is more than meets the eye with cell therapy manufacturing than just scalability. Listen to our discussion with Lonza, ZIOPHARM, MSKCC and Stanford Center for Cancer Cell Therapy on the lessons learned from early technology evaluations to the commercial approval of immunotherapies.

White Papers

NEWLY ADDED!

CAR-TCR: White Paper

Cancer Care in the Time of COVID-19

DelveInsight

NEWLY ADDED!

CAR-TCR: White Paper

Remdesivir in COVID-19

DelveInsight

Articles

NEWLY ADDED!

CAR-TCR: Article

CAR T: Fireside Chat

Helen Tayton- Martin, CBO, Adaptimmune
André Choulika, CEO,Cellectis
Michael Koslowski, CMO, GammaDelta Therapeutics
Dolores Schendel, CEO, Medigene
Jacob Plieth, Senior Reporter,Vantage Analysis

Presentations

NEWLY ADDED!

CAR-TCR Presentation

CAR T: Continuation in a Revolution of Cancer Therapeutics

Dr. Joseph McGuirk, Professor of Medicine Schutte Speas Professor of Hematology Oncology. Medical Director, BMT and Cellular Therapeutics. Division Director, Hematologic Malignancies and Cellular Therapeutics

NEWLY ADDED!

CAR-TCR Presentation

Overcoming Treatment
Resistance to T Cell
Therapy

Adrian Bot, M.D., Ph.D.
Vice President, Translational Medicine

NEWLY ADDED!

CAR-TCR Presentation

Navigating Regulatory Requirements for
Early Phase CAR-T Clinical Studies

Elena Spanjaard, Global Head of Regulatory Affairs, Celyad

NEWLY ADDED!

CAR-TCR Presentation

CAR T Cells for Solid Tumours, To Do List

Francesco M. Marincola, Chief Research Officer, Refuge Biotechnologies

NEWLY ADDED!

CAR-TCR Presentation

Identification of Novel Shared Targets for Solid Tumors

Hans-Peter Gerber, Ph.D. SVP & CSO,3T Biosciences

NEWLY ADDED!

CAR-TCR Presentation

Cross-Sector Efforts to Advance Gene & Cell Therapy Manufacturing

Michael Lehmicke, Director, Science & Industry Affairs

NEWLY ADDED!

CAR-TCR Presentation

The Bridge to Curative Cellular Therapies

Paul Rennert, CAR-TCR Summit 2019

NEWLY ADDED!

CAR-TCR Presentation

Next generation, contextual regulation of CAR T function in vivo:

Zhifen Yang, Senior Scientist, Refuge Biotechnologies

Magazines

NEWLY ADDED!

CAR-TCR Magazine - Q1

Interviews

NEWLY ADDED!

CAR-TCR Conversation with...

Laura Pierce, Biomedical Engineer, NIST

In this conversation, Laura expresses her opinions on the greatest challenges currently facing developers of cell therapies, as well as her thoughts on what the future might hold for CAR-TCR.

NEWLY ADDED!

CAR-TCR Conversation with...

Sarah Snykers, Quality Control Manager, Celyad

In this conversation, Sarah shares her thoughts on the best direction for cell therapy drug developers to take, in order to drive the progression of CAR-TCR treatments.

CAR-TCR Conversation with...

Peter Emtage, Senior Vice President, Head of Cell Therapy Research, Kite, a Gilead Company

In this conversation, Peter shares his views on the clinical and commercial progression of CAR-T therapies after a whirlwind few years.

View Full Interview

CAR-TCR Conversation with...

David Sourdive, Executive Vice President, Technical Operations & Co-founder, Cellectis

In this conversation, David discusses the disruptive genetic engineering approaches developed to create efficacious, next generation CAR and TCR therapies.

View Full Interview